Free Trial
ASX:BNO

Bionomics (BNO) Stock Price, News & Analysis

About Bionomics Stock (ASX:BNO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
386,458 shs
Average Volume
N/A
Market Capitalization
$13.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Receive BNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNO Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Bionomics ADR (BNOX) Earnings Dates & Reports
Bionomics Ltd: Bionomics' Half-Year Report
See More Headlines

BNO Stock Analysis - Frequently Asked Questions

Bionomics Limited (ASX:BNO) posted its quarterly earnings results on Friday, February, 15th. The company reported ($0.02) EPS for the quarter. Bionomics had a negative trailing twelve-month return on equity of 116.12% and a negative net margin of 14,558.34%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include McDermott International (MDR), Pacific Drilling (PACDQ), OreCorp (ORR), ORBCOMM (ORBC), Lithium Power International (LPI), Lithium Australia (LIT) and Coca-Cola (KO).

Company Calendar

Last Earnings
2/15/2019
Today
5/05/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:BNO
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,910,000.00
Net Margins
-14,558.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.02 million
Price / Cash Flow
2.69
Book Value
A$1.09 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,470,000,000
Free Float
N/A
Market Cap
$13.22 million
Optionable
Not Optionable
Beta
2.13
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (ASX:BNO) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners